You can buy or sell REGENXBIO and other stocks, options, ETFs, and crypto commission-free!
REGENXBIO Inc. Common Stock, also called REGENXBIO, is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Read More The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Simply Wall StMar 12
Is REGENXBIO Inc. (NASDAQ:RGNX) As Strong As Its Balance Sheet Indicates?
Mid-caps stocks, like REGENXBIO Inc. (NASDAQ:RGNX) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. RGNX’s financial liquidity and debt position will be analysed in this article, to get an idea of w...
Stock Price, News, & Analysis for Regenxbio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment ...
Yahoo FinanceMar 5
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO Inc. RGNX was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 18.6% in the past one-month time frame. The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent...
Expected May 7, After Hours